Why Regulatory Risk Planning Matters at the IND Stage
Early development programs face multiple uncertainties:
- Limited human safety data
- Evolving CMC processes and analytical methods
- Emerging nonclinical signals that require careful interpretation
- Novel modalities without extensive regulatory precedent
Without a structured approach, teams may either over-engineer (wasting time and resources) or under-prepare (inviting avoidable regulatory questions).
Regulatory risk planning provides a framework to:
- Identify and prioritize potential issues
- Develop mitigation strategies early
- Align cross-functional teams around a realistic plan
- Inform interactions with agencies such as the FDA
Identifying Key Regulatory Risks Before IND
Effective planning starts with a systematic risk identification exercise across:
- Nonclinical Program
- Are species and models appropriate and justified?
- Do toxicology data adequately support the proposed starting dose?
- Are there safety signals that require additional follow-up?
- CMC Readiness
- Is the manufacturing process sufficiently controlled for early clinical supply?
- Are analytical methods robust enough to support release and stability?
- Are there known impurities, variants, or attributes that may concern regulators?
- Clinical Design
- Is the rationale for population, dosing, and escalation strategy sound?
- Are endpoints and safety monitoring aligned with risk profile and mechanism?
- Are we prepared to justify risk–benefit at first-in-human?
- Regulatory Strategy and Precedent
- Are there relevant guidances, precedents, or advisory committee outcomes?
- Could the program benefit from designations (e.g., Fast Track, Breakthrough)?
Building a Risk Register and Mitigation Plan
Once risks are identified, they should be documented in a regulatory risk register that includes:
- Description of each risk
- Likelihood and impact assessment
- Proposed mitigation steps
- Owner and target timelines
Examples of mitigation activities:
- Adding or refining nonclinical studies
- Strengthening analytical or process controls
- Adjusting starting dose or escalation plan
- Planning early regulatory interactions (e.g., pre-IND meetings)
Making the Most of FDA Pre-IND Meetings
A well-planned pre-IND meeting can significantly reduce uncertainty. To maximize value:
- Clearly define questions around CMC, nonclinical, and clinical design
- Provide focused briefing materials that highlight your risk analysis
- Demonstrate that you have considered regulatory expectations and precedents
- Be open to feedback and ready to adapt the plan accordingly
Regulators are more likely to engage constructively when they see a disciplined approach to risk.
How BioBoston Consulting Supports IND Regulatory Risk Planning
BioBoston Consulting helps early-stage teams design and execute strategic regulatory plans by:
- Conducting cross-functional regulatory risk assessments for IND
- Advising on nonclinical, CMC, and clinical strategies that align with guidances
- Preparing and reviewing pre-IND briefing documents and questions
- Coaching teams for regulatory meetings and interpreting feedback
- Supporting ongoing adjustments as new data emerge
With input from former regulators and senior industry experts, we help you move from concept to first-in-human with a clear, defensible plan—reducing surprises and keeping your development on track.
